Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19
| Errataetall: |
CommentOn: J Med Virol. 2020 Jul;92(7):814-818. - PMID 32253759 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:128 |
|---|---|
| Enthalten in: |
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology - 128(2020) vom: 24. Juli, Seite 104443 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hassoun, Ali [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 19.06.2020 Date Revised 17.10.2023 published: Print-Electronic CommentOn: J Med Virol. 2020 Jul;92(7):814-818. - PMID 32253759 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jcv.2020.104443 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310081963 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310081963 | ||
| 003 | DE-627 | ||
| 005 | 20231225135323.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jcv.2020.104443 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1033.xml |
| 035 | |a (DE-627)NLM310081963 | ||
| 035 | |a (NLM)32425661 | ||
| 035 | |a (PII)S1386-6532(20)30185-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hassoun, Ali |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.06.2020 | ||
| 500 | |a Date Revised 17.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: J Med Virol. 2020 Jul;92(7):814-818. - PMID 32253759 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 700 | 1 | |a Thottacherry, Elizabeth Dilip |e verfasserin |4 aut | |
| 700 | 1 | |a Muklewicz, Justin |e verfasserin |4 aut | |
| 700 | 1 | |a Aziz, Qurrat-Ul-Ain |e verfasserin |4 aut | |
| 700 | 1 | |a Edwards, Jonathan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology |d 1997 |g 128(2020) vom: 24. Juli, Seite 104443 |w (DE-627)NLM097223964 |x 1873-5967 |7 nnns |
| 773 | 1 | 8 | |g volume:128 |g year:2020 |g day:24 |g month:07 |g pages:104443 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jcv.2020.104443 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 128 |j 2020 |b 24 |c 07 |h 104443 | ||